Press Releases Archives

CCRM, OmniaBio and Avectas Partner to Improve Cell Therapy Manufacturing

TORONTO, CANADA & DUBLIN IRELAND — June 15th, 2026 — CCRM and its CDMO subsidiary OmniaBio Inc., today announced an agreement with Avectas Limited (“Avectas”) to evaluate its automated, integrated and scalable cell therapy manufacturing platform. The evaluation will explore how Avectas’ platform could complement CCRM’s growing global network and OmniaBio’s efforts to enable more […]

CCRM, OmniaBio and Avectas Partner to Improve Cell Therapy Manufacturing Read More »

OmniaBio Inc. Awarded Drug Establishment License (DEL) by Health Canada, Certifying Canada’s Largest Cell & Gene Therapy CDMO

HAMILTON & TORONTO ONTARIO – December 23, 2025 – OmniaBio Inc., Canada’s largest cell and gene therapy (CGT) contract development and manufacturing organization (CDMO), today announced that Health Canada has awarded the company a Drug Establishment License (DEL), confirming the maturity and compliance of its Good Manufacturing Practices (GMP). Secured less than one year after opening the Hamilton,

OmniaBio Inc. Awarded Drug Establishment License (DEL) by Health Canada, Certifying Canada’s Largest Cell & Gene Therapy CDMO Read More »

OmniaBio Inc. and BrainChild Bio Announce Collaboration to Accelerate CAR-T Cell therapy Development in Brain Cancer

TORONTO, ONTARIO & BOSTON, MA – October 1st, 2025 – OmniaBio Inc., a next generation contract development and manufacturing organization (CDMO) pioneering the manufacturing of cell and gene therapies (CGT) with robotics and artificial intelligence, and BrainChild Bio Inc, a clinical-stage biotechnology company developing Chimeric Antigen Receptor T-cell (CAR-T) therapies to treat solid tumors in

OmniaBio Inc. and BrainChild Bio Announce Collaboration to Accelerate CAR-T Cell therapy Development in Brain Cancer Read More »

Federal government announces support for cutting-edge, AI- and robotics-enabled cell and gene therapy manufacturing

From: Innovation, Science and Economic Development Canada OmniaBio’s expanded facility in Hamilton seeks to drive a 5X increase in manufacturing efficiency while reducing production and supply costs by up to 50%, facilitating patient access to life-saving treatments for chronic diseases, including cancer March 22, 2025 – Hamilton, Ontario The Government of Canada is working

Federal government announces support for cutting-edge, AI- and robotics-enabled cell and gene therapy manufacturing Read More »

LineaBio submits Drug Master File for Linea 1 GMP iPSC line to U.S. Food and Drug Administration

November 20, 2024 (Toronto, Ontario) – LineaBio, a cell line company, today announced it has submitted a Type II Drug Master File (DMF) to the U.S. Food and Drug Administration (FDA) for its flagship unmodified, off-the-shelf, Good Manufacturing Practices (GMP)-compliant induced pluripotent stem cell (iPSC) line, Linea 1. LineaBio was launched in 2023 by parent companies CCRM,

LineaBio submits Drug Master File for Linea 1 GMP iPSC line to U.S. Food and Drug Administration Read More »

OmniaBio Announces Opening of New Commercial Manufacturing Facility in Canada, Bringing Life-Saving Cell and Gene Therapies to Patients

The site will add state-of-the-art CGT capacity and employ artificial intelligence and automation to achieve critical product supply efficiencies for North American and global biotherapy clients. Hamilton, ON., October 17, 2024 – Today OmniaBio Inc. will announce the opening of a new North American cell and gene therapy (CGT) manufacturing and artificial intelligence (AI) centre of

OmniaBio Announces Opening of New Commercial Manufacturing Facility in Canada, Bringing Life-Saving Cell and Gene Therapies to Patients Read More »

Somite Therapeutics and OmniaBio Inc. Announce Collaboration to Advance Somite’s Cell Therapy Flagship Program

CDMO collaboration propels cell replacement therapy targeting Duchenne muscular dystrophy forward, with consequences for the role of AI in cell therapy. September 9, 2024 (BOSTON, MA and HAMILTON, Ontario) – Somite Therapeutics, a tech-bio company harnessing big data and AI to pioneer novel cell replacement therapies, and OmniaBio Inc., a technology-driven cell and gene therapy CDMO

Somite Therapeutics and OmniaBio Inc. Announce Collaboration to Advance Somite’s Cell Therapy Flagship Program Read More »

LineaBio launches off-the-shelf GMP iPSC lines to accelerate iPSC-based cell therapies

CCRM and OmniaBio spin-off provides high-quality iPSC lines that expedite time to GMP by 12 months and reduce cell line development costs by up to 60%. July 30, 2024 (Toronto, Ontario) – LineaBio, a cell line company, today announced the launch of its catalogue of off-the-shelf induced pluripotent stem cell (iPSC) lines. The off-the-shelf iPSC

LineaBio launches off-the-shelf GMP iPSC lines to accelerate iPSC-based cell therapies Read More »

OmniaBio announces Kenneth L. Harris as Chief Strategy Officer and Head of AI

June 12, 2024 (Hamilton, Ontario) – OmniaBio Inc. is pleased to announce the appointment of Kenneth (Ken) L. Harris as its Chief Strategy Officer and Head of Artificial Intelligence (AI), strengthening its mandate of bringing maturity to cell and gene therapy (CGT) through focused CGT expertise in contract development and manufacturing. Harris, a seasoned executive

OmniaBio announces Kenneth L. Harris as Chief Strategy Officer and Head of AI Read More »

NGen Unveils $86.7 Million in New Advanced Manufacturing Projects at N3 Summit

15 New projects underway to build world leading advanced manufacturing capabilities in Canada. TORONTO, ON, February 8, 2024 – NGen has announced over $32.3 million in Global Innovation Cluster funding for 15 new advanced manufacturing projects. With industry contributions of $54.4 million, the 15 projects are valued at a total of $86.7 million. The announcement

NGen Unveils $86.7 Million in New Advanced Manufacturing Projects at N3 Summit Read More »